Related Experiment Video
Updated: Jul 14, 2026
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Ta-Jen Wu1, Horng-Yih Ou, Chien-Wen Chou
1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Annals of Clinical and Laboratory Science
|May 25, 2007
Summary
Micronized fenofibrate effectively reduced inflammatory markers like hs-CRP and ESR in type 2 diabetes patients with hyperlipidemia. The drug improved lipid profiles but did not impact proinsulin levels.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background:
- Type 2 diabetes and hyperlipidemia often coexist, increasing cardiovascular risk.
- Inflammation plays a significant role in the pathogenesis of these conditions.
- Proinsulin levels can serve as a marker of pancreatic stress.
Purpose of the Study:
- To evaluate the impact of micronized fenofibrate on inflammatory markers and proinsulin in patients with type 2 diabetes and hyperlipidemia.
- To assess changes in lipid profile parameters following micronized fenofibrate treatment.
Main Methods:
- A 12-week study involving 39 patients with type 2 diabetes and hyperlipidemia treated with micronized fenofibrate (200 mg/day).
- Measurement of erythrocyte sedimentation rate (ESR), fibrinogen, high-sensitivity C-reactive protein (hs-CRP), proinsulin, and lipid profile at baseline and after treatment.
- Statistical analysis to determine significant changes and correlations.
Main Results:
- Micronized fenofibrate significantly improved lipid profiles, reducing triglycerides, cholesterol, and non-HDL-cholesterol while increasing HDL-cholesterol.
- Significant reductions were observed in inflammatory markers: hs-CRP, ESR, and fibrinogen.
- No significant change in proinsulin levels was noted after 12 weeks of therapy.
Conclusions:
- Micronized fenofibrate demonstrates efficacy in reducing key inflammatory markers and improving lipid profiles in patients with type 2 diabetes and hyperlipidemia.
- The drug's effect on proinsulin levels warrants further investigation.
- The findings suggest a potential benefit of micronized fenofibrate in managing the complex metabolic and inflammatory landscape of these patients.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...